Karolinska Development AB (publ) (KDEV.ST)
| Previous Close | 1.2240 |
| Open | 1.2240 |
| Bid | 1.2460 x 0 |
| Ask | 1.2720 x 0 |
| Day's Range | 1.2020 - 1.2760 |
| 52 Week Range | 1.1500 - 1.9480 |
| Volume | |
| Avg. Volume | 229,368 |
| Market Cap | 344.307M |
| Beta (5Y Monthly) | 0.21 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.0200 |
| Earnings Date | Nov 15, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
GlobeNewswireKarolinska Development’s portfolio company Umecrine Cognition presents new preclinical Parkinson’s data on golexanolone at the scientific conference, INBC 2024
STOCKHOLM, SWEDEN – October 17, 2024. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company Umecrine Cognition will present new preclinical data on golexanolone, showing retained dopamine signalling in Parkinson’s disease, at the 10th International Conference on Neurology and Brain Disorders 2024 in Baltimore, Maryland, US, during October 21-23. Parkinson’s disease is a progressive neurodegenerative disease hallmarked by motor symptoms and disrupted cognit
- GlobeNewswire
Notice of Extraordinary General Meeting in Karolinska Development AB (publ)
The shareholders of Karolinska Development AB (publ), reg. no. 556707-5048, (“Karolinska Development” or the “Company”) are invited to the Extraordinary General Meeting (“EGM”), on Wednesday, November 13, 2024, at 11:00 (CET), at Cirio Law Firm, Biblioteksgatan 9, in Stockholm. Registration for the EGM will commence at 10:30 (CET). The Board of Directors has resolved that shareholders shall have the right to exercise their voting rights in advance through postal voting pursuant to item 13 in the
